A Dose-Optimization Study for the Initial Treatment of Dysplastic Barrett's Esophagus With truFreeze™ Spray Cryotherapy

Overview

Información sobre este estudio

The primary objective of this study is to determine the percentage segment regression after spray cryotherapy in a dose-escalation study performed in patients with dysplastic Barrett's Esophagus (BE) using truFreeze spray cryotherapy within the currently recommended therapeutic range. Secondary objectives are the determination of safety related outcomes such as esophageal stricture.

Elegibilidad para la participación

Los requisitos de elegibilidad de los participantes incluyen la edad, el sexo, el tipo y el estadio de la enfermedad, y los problemas de salud o tratamientos previos. Las pautas difieren de un estudio a otro e identifican quiénes pueden o no pueden participar. No hay garantía de que cada persona elegible que desee participar en un ensayo se inscribirá. Comunícate con el equipo del estudio para analizar la elegibilidad del estudio y la posible participación.

This study has been terminated

Inclusion Criteria:

  • English speaking males or females aged 18 to 85 who are candidates for sedated endoscopy with treatment of BE.
  • At least 3 centimeters segment length of Barrett's Esophagus (BE) with or without circumferential involvement (i.e. CxM3) and with high grade or low grade dysplasia based on pathology results from 4 quadrant biopsies taken every 1-2 centimeter throughout the BE. All readings of dysplasia will be confirmed by an expert pathologist.
  • Willing to undergo spray cryotherapy and judged by patient's physician as an appropriate candidate for this therapy.
  • Able to read, comprehend, and complete the informed consent form

Exclusion Criteria:

  • Bleeding disorder or other contraindication of spray cryotherapy.
  • History of partial or complete esophagectomy.
  • Current or past diagnosis of invasive esophageal cancer (previous intramucosal cancer is allowable, if removed by endoscopic mucosal resection with histologically confirmed negative lateral and deep margins).
  • Pregnant women
  • Contraindication to endoscopic spray cryotherapy as outlined in the directions for use for the device
  • Previous endoscopic ablation treatment (such as radiofrequency ablation (RFA) or photodynamic therapy (PDT)).
  • Previous chest external beam radiation therapy.
  • Previous wide-area endoscopic resection or submucosal dissection. Previous focal mucosal resection is permitted (maximum 2 previous EMR's of 2cm or less removed representing less than 25% of the circumference of the esophagus removed).

Sedes participantes de Mayo Clinic

Los estatus de los estudios cambian con frecuencia. Comunícate con el equipo del estudio para obtener la información más actualizada acerca de la posibilidad de participar.

Sede de Mayo Clinic Estatus

Jacksonville, Fla.

Investigador principal de Mayo Clinic

Herbert Wolfsen, M.D.

Cerrado para la inscripción

More information

Publicaciones

Publications are currently not available
.
CLS-20149013

Mayo Clinic Footer